SMOLDERING PLASMA CELL MYELOMA

This study tests whether adding daratumumab to standard lenalidomide and dexamethasone can delay or prevent smoldering myeloma from becoming active multiple myeloma. About 288 people with high-risk smoldering myeloma will participate. The goal is to see if the combination improve…

This study tests a drug called iberdomide, alone or with dexamethasone, in people with smoldering multiple myeloma at intermediate or high risk of developing active cancer. The goal is to see if the treatment can shrink or control the cancer cells and delay progression to symptom…

This study looks at whether non-drug approaches like physical activity, intermittent fasting, or adding a common beta-blocker (propranolol) can improve immune function and quality of life in people with multiple myeloma or related blood disorders. Researchers will measure changes…

This study looks at the quality of life of people with two early blood conditions: monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma. Researchers want to learn about the most common symptoms and concerns these patients face. Participants will fi…

This study follows 200 people with early blood conditions (MGUS or smoldering myeloma) that sometimes turn into multiple myeloma. Researchers will track age, blood protein levels, bone marrow cells, and genetic markers to see who progresses and who doesn't. No treatments are give…